Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer

Key Points

• This research aims to explore the role of GPR34 in enhancing anti-tumor immunity in pancreatic cancer.
• Combined GPR34 antagonist with chemotherapy and surufatinib in preclinical models.
• Assessed anti-tumor immune responses following treatment.
• Significant enhancement of anti-tumor responses observed in models treated with GPR34 antagonist.
• GPR34 identified as a promising therapeutic target for improving pancreatic cancer treatment.